{"id":3511,"date":"2014-12-23T13:36:05","date_gmt":"2014-12-23T18:36:05","guid":{"rendered":"https:\/\/fomatmedical.com\/?p=3511"},"modified":"2026-04-28T20:46:34","modified_gmt":"2026-04-29T03:46:34","slug":"vancomycin-kidney-damage-in-children","status":"publish","type":"post","link":"https:\/\/fomatmedical.com\/es\/blogs-updates\/vancomycin-kidney-damage-in-children\/","title":{"rendered":"Las dosis altas de vancomicina aumentan el riesgo de da\u00f1o renal en los ni\u00f1os"},"content":{"rendered":"<div data-test-render-count=\"1\">\n<div class=\"group\">\n<div class=\"contents\">\n<div class=\"group relative relative pb-3\" data-is-streaming=\"false\">\n<div class=\"font-claude-response relative leading-[1.65rem] [&amp;_pre&gt;div]:bg-bg-000\/50 [&amp;_pre&gt;div]:border-0.5 [&amp;_pre&gt;div]:border-border-400 [&amp;_.ignore-pre-bg&gt;div]:bg-transparent [&amp;_.standard-markdown_:is(p,blockquote,h1,h2,h3,h4,h5,h6)]:pl-2 [&amp;_.standard-markdown_:is(p,blockquote,ul,ol,h1,h2,h3,h4,h5,h6)]:pr-8 [&amp;_.progressive-markdown_:is(p,blockquote,h1,h2,h3,h4,h5,h6)]:pl-2 [&amp;_.progressive-markdown_:is(p,blockquote,ul,ol,h1,h2,h3,h4,h5,h6)]:pr-8\">\n<div>\n<div class=\"standard-markdown grid-cols-1 grid [&amp;_&gt;_*]:min-w-0 gap-3 standard-markdown\"><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"flex justify-start\" role=\"group\" aria-label=\"Message actions\">\n<div class=\"text-text-300\">\n<div class=\"text-text-300 flex items-stretch justify-between\">\n<div class=\"w-fit\" data-state=\"closed\">\n<div class=\"relative text-text-500 group-hover\/btn:text-text-100\">\n<div class=\"transition-all opacity-100 scale-100\">\n<p class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\">Vancomycin kidney damage in children is a documented and measurable risk. A study from Johns Hopkins Children&#8217;s Center found that hospitalized children receiving high dose IV vancomycin for drug resistant infections face a real risk of kidney injury \u2014 one that rises with every additional dose. The findings, published in the <a class=\"underline underline underline-offset-2 decoration-1 decoration-current\/40 hover:decoration-current focus:decoration-current\" href=\"https:\/\/journals.sagepub.com\/home\/aop\" target=\"_blank\" rel=\"noopener\">Annals of Pharmacotherapy<\/a>, call for more careful prescribing and faster development of safer alternatives.<\/p>\n<h3 class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"><strong>What Is Vancomycin and Why Are Doses Rising?<\/strong><\/h3>\n<p class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\">Vancomycin is an antibiotic reserved for drug resistant bacterial infections that do not respond to standard treatment. It has been used safely for decades. However, the rise of MRSA and similar resistant bacteria prompted new dosing guidelines in 2009, calling for higher doses when a resistant infection is suspected.<\/p>\n<p class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\">Those guidelines were written for adults. Many pediatric hospitals began applying the same high dose approach to children to ensure the drug reaches levels strong enough to eliminate resistant bacteria. The result has been a growing concern around vancomycin kidney damage in children receiving prolonged or high dose therapy.<\/p>\n<h3 class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"><strong>Vancomycin Kidney Damage in Children at High Doses<\/strong><\/h3>\n<p class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\">Researchers analyzed records from 175 children treated with vancomycin at Johns Hopkins between 2009 and 2010. They found that 14% developed kidney damage during treatment.<\/p>\n<p class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\">The risk followed a clear dose related pattern. Every 5 milligram per kilogram increase in daily dose raised the risk of vancomycin kidney damage in children by 16%. A 44 pound child receiving 1,600 milligrams per day carries a 16% higher risk than a child of the same size receiving 1,200 milligrams daily.<\/p>\n<p class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\">Other factors that increased risk included:<\/p>\n<ul class=\"[li_&amp;]:mb-0 [li_&amp;]:mt-1 [li_&amp;]:gap-1 [&amp;:not(:last-child)_ul]:pb-1 [&amp;:not(:last-child)_ol]:pb-1 list-disc flex flex-col gap-1 pl-8 mb-3\">\n<li class=\"whitespace-normal break-words pl-2\">Longer treatment duration \u2014 each additional day raised risk by 11%<\/li>\n<li class=\"whitespace-normal break-words pl-2\">Combined use of other kidney taxing medications \u2014 children on more than one such drug showed five times higher risk<\/li>\n<\/ul>\n<p class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\">Children who developed kidney damage received vancomycin for an average of eight days, compared to four days among those who did not. Their average daily dose was also 10 milligrams per kilogram higher.<\/p>\n<h3 class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"><strong>Is the Kidney Damage Permanent?<\/strong><\/h3>\n<p class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\">In most cases, no. The researchers emphasize that vancomycin kidney damage in children is generally reversible once treatment stops. Still, the complication is serious enough to warrant close monitoring throughout the course of therapy.<\/p>\n<p class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\">Clinicians are advised to test kidney filtration rates periodically throughout vancomycin therapy, particularly in children receiving high doses or combination drug regimens.<\/p>\n<h3 class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"><strong>What Should Clinicians Do?<\/strong><\/h3>\n<p class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\">The study team recommends that decisions to use high dose vancomycin in children account for the child&#8217;s overall health and any other medications being used at the same time. Kidney function should be monitored carefully and frequently throughout treatment.<\/p>\n<p class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\">Senior investigator Carlton Lee, Pharm.D., M.P.H., summed up the challenge: balancing a dose high enough to treat life threatening infections against the real, if small, risk of kidney harm.<\/p>\n<p class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\">Lead author Elizabeth Sinclair, Pharm.D., stressed that pediatric dosing decisions should be based on data from studies in children \u2014 not extrapolations from adult patients.<\/p>\n<h4 class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"><strong>A Push for Safer Alternatives<\/strong><\/h4>\n<p class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\">Both investigators point to the same conclusion: what the field needs most are new drugs capable of treating resistant infections without the kidney risk. Johns Hopkins is actively pursuing this goal through several <a class=\"underline underline underline-offset-2 decoration-1 decoration-current\/40 hover:decoration-current focus:decoration-current\" href=\"https:\/\/fomatmedical.com\/blogs-updates\/\">clinical research studies<\/a> in pediatric patients.<\/p>\n<p class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\">Clinical research plays a critical role in developing safer treatment options for pediatric patients. Participation in trials studying new antibiotic therapies gives children access to emerging treatments while generating the evidence clinicians need to make dosing decisions grounded in real world data rather than adult extrapolation.<\/p>\n<h3 class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\"><strong>Vancomycin Kidney Damage in Children: Key Takeaways for Clinicians<\/strong><\/h3>\n<p class=\"font-claude-response-body break-words whitespace-normal leading-[1.7]\">The risk of vancomycin kidney damage in children is real, measurable, and largely preventable with careful monitoring. High doses, prolonged therapy, and concurrent use of kidney-taxing medications each compound the risk. Cautious prescribing and frequent kidney function testing remain the most effective tools available until safer alternatives reach the market.<\/p>\n<\/div>\n<div class=\"absolute top-0 left-0 transition-all opacity-0 scale-50\">Source: Johns Hopkins | Originally published December 22, 2014<\/div>\n<\/div>\n<\/div>\n<div class=\"w-fit\" data-state=\"closed\">\n<div class=\"text-text-500 group-hover\/btn:text-text-100\"><\/div>\n<\/div>\n<div class=\"w-fit\" data-state=\"closed\">\n<div class=\"text-text-500 group-hover\/btn:text-text-100\"><\/div>\n<\/div>\n<div class=\"flex items-center\">\n<div class=\"w-fit\" data-state=\"closed\">\n<div class=\"text-text-500 group-hover\/btn:text-text-100\"><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"h-px w-full pointer-events-none\" aria-hidden=\"true\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>El da\u00f1o renal causado por la vancomicina en los ni\u00f1os es un riesgo documentado y cuantificable. Un estudio del Centro Infantil Johns Hopkins revel\u00f3 que los ni\u00f1os hospitalizados que reciben dosis altas de vancomicina por v\u00eda intravenosa para tratar infecciones resistentes a los medicamentos corren un riesgo real de sufrir da\u00f1o renal, un riesgo que\u2026<\/p>","protected":false},"author":3,"featured_media":94455,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"content-type":"","footnotes":""},"categories":[968],"tags":[940,1089,1065],"class_list":["post-3511","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blogs-updates","tag-medical-research","tag-pediatric","tag-pharma"],"acf":[],"_links":{"self":[{"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/posts\/3511","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/comments?post=3511"}],"version-history":[{"count":0,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/posts\/3511\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/media\/94455"}],"wp:attachment":[{"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/media?parent=3511"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/categories?post=3511"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fomatmedical.com\/es\/wp-json\/wp\/v2\/tags?post=3511"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}